ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance.

Xu, Chao; Xie, Yongjie; Xie, Peng; Li, Jianming; Tong, Zhongsheng; Yang, Yanfang

Xu, Chao; Xie, Yongjie; Xie, Peng; Li, Jianming; Tong, Zhongsheng; Yang, Yanfang.

Afiliación

Xu C; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, North Huanhu West Road, Tianjin, 300060, China.
Xie Y; National Clinical Research Center for Cancer, Tianjin Cancer Hospital Airport Hospital, Tianjin, 300060, China.
Xie P; Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Li J; Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Tong Z; Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Yang Y; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, North Huanhu West Road, Tianjin, 300060, China. tongzhongsheng@tjmuch.com.

Discov Oncol ; 14(1): 191, 2023 Oct 24.

Article en En | MEDLINE | ID: mdl-37875591

Palabras clave

Immune biomarkers; Immunotherapy resistance; TNBC; ZDHHC9

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Discov Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google